- socially bharat
- November 6, 2024
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024
San Mateo, Calif., United States: Five-year results of Phase 3 SEQUOIA study demonstrate durable benefits of BRUKINSA in patients with